Lv1
18 积分 2023-08-31 加入
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
8小时前
待确认
A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies
10小时前
已完结
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
5天前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
5天前
已完结
Synthetic lethal strategies for the development of cancer therapeutics
5天前
已完结
Next-Gen PARP Inhibitor Effective in Breast Cancer
14天前
已关闭
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
1个月前
已完结
Initial Clinical Experience with [ 177 Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry
2个月前
已完结
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design
3个月前
已完结
[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
3个月前
已关闭
皖公网安备34019202002308
